Mercury Medical will be the exclusive US distributor for ABM Respiratory Care’s airway clearance therapy devices, according to a press release from ABM. The agreement makes Mercury Medical the US exclusive distribution partner of ABM Respiratory Care’s BiWaze Cough and BiWaze Clear ACT devices for non-government acute care facilities.

ABM’s BiWaze Cough is a multi-therapy system that combines cough assist, lung expansion and high frequency oscillation. The device breaks up and then removes mucus from the lungs by applying positive air pressure to the airway and then rapidly shifting to negative air pressure, according to the company’s website. Meanwhile, ABM’s BiWaze Clear is an ACT system that delivers oscillating lung expansion (OLE) therapy in the hospital, post-acute, and home care environments.

“Our partnership with Mercury Medical marks a significant milestone for ABM Respiratory Care,” said Greg Miller, CEO of ABM Respiratory Care. “We are excited to expand the reach of our innovative BiWaze portfolio through their specialized salesforce. This partnership underscores our commitment to advancing respiratory care and improving patient outcomes.”

ABM says Mercury Medical is well-positioned to ensure efficient distribution, comprehensive support, and training of the BiWaze portfolio in the acute care market.

“Mercury Medical’s partnership with ABM Respiratory Care is in strong alignment with our mission to deliver clinically differentiated critical care technology that saves lives throughout the world,” said John Gargaro MD, President and CEO of Mercury Medical. “With our long history and experience in introducing innovative technology to the market, we are excited to contribute to advancing clinical practice in respiratory care.”